CONCORDBIO Concord Biotech Q3 FY25 results (Oct–Dec 2024) and concall
Concord Biotech reported a stable but muted Q3 FY25, characterized by revenue 'lumpiness' as global clients phased procurement into Q4. While quarterly growth was flat, the 9-month performance remains robust with 10% revenue growth and significant traction in the formulations business. Management is pivoting towards a medium-term CDMO strategy and preparing for the imminent launch of its injectable facility to drive future margins.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 310 | 244 |
| EBITDA | 137 | 98 |
| Net profit | 99 | 74 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
